Neogenomics (NEO) Cash & Current Investments (2010 - 2026)

Neogenomics (NEO) has 17 years of Cash & Current Investments data on file, last reported at $145.5 million in Q2 2026.

• Quarterly Cash & Current Investments fell 11.09% year-over-year to $145.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $145.5 million (down 11.09% YoY) and the FY2025 annual result came in at $159.6 million, down 58.74% from the prior year.
• Cash & Current Investments steadied at $145.5 million in Q2 2026, from $146.1 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $481.4 million in Q1 2022 to a low of $145.5 million in Q2 2026.
• A 5-year average of $342.1 million and a median of $387.8 million in 2024 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2024 — Cash & Current Investments declined 3.59% — and 2026, when it plunged 59.19%.
• Tracing NEO's Cash & Current Investments over 5 years: stood at $438.0 million in 2022, then declined by 5.2% to $415.2 million in 2023, then dropped by 6.83% to $386.8 million in 2024, then slumped by 58.74% to $159.6 million in 2025, then slipped by 8.82% to $145.5 million in 2026.
• The last three Cash & Current Investments figures came in at $145.5 million (Q2 2026), $146.1 million (Q1 2026), and $159.6 million (Q4 2025), per Business Quant data.